BEVERLY, MA – May 29, 2019 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company will be attending the 2019 BIO International Convention, held June 3-6, in Philadelphia, Pennsylvania.
Industry representatives interested in scheduling one-on-one meetings with Innovation Pharmaceuticals management can email the Company, with available timeslots, at firstname.lastname@example.org.
The three day-long conference is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
Innovation Pharmaceuticals plans to leverage the conference to continue to build and strengthen business development relationships across its clinical pipeline, which includes: Brilacidin, an immunomodulatory drug candidate with anti-inflammatory and antibiotic properties granted Fast Track designation by the Food and Drug Administration (FDA); and Kevetrin, an FDA Orphan Drug-designated p53-modulating anti-cancer drug candidate.
“It’s an exciting time for the Company as we work toward solidifying Pharma partnerships—advancing ongoing licensing efforts that are already well underway, as well as generating interest among other potential partners,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Both Brilacidin and Kevetrin are Platform drug candidates with multiple therapeutic applications given unique mechanisms of action and properties. We feel strongly that these drug candidates hold tremendous treatment potential for improving the lives of countless patients and look forward to continuing to evaluate them in clinical trials.”
Additional 2019 Bio International Convention details can be found by clicking here.